Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model

Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model

Background and objectivesBoth gumarontinib and savolitinib have demonstrated efficacy in treating non-small-cell lung cancer (NSCLC) with tumors harboring mesenchymal–epithelial transition factor gene exon 14 (METex14) skipping. However, the comparison of their efficacy and pharmacoeconomics profile...

Full description

Saved in:
Bibliographic Details
Main Authors: Gang Fang, Zhipeng Pi, Yiping An, Xinxin Cao, Wei Li, Xiangjun Zhu, Jinxi Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness analysis
METex14
non-small-cell lung cancer
gumarontinib
savolitinib
MAIC
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1400422/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items